8-K filing — Cocrystal Pharma, Inc. (COCP)
Filed: 2026-09-09 AccNo: 0001493152-26-041877 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Challenge Study Of CDI-988; Says No Serious Adverse Events To Date, Preliminary Efficacy Results Expected Late 2026 Or Early 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from
Cocrystal Pharma shares are trading higher after the company announced a $5 million private placement with OPKO Health.